Serum MicroRNA-Based Risk Prediction for Stroke

被引:57
|
作者
Sonoda, Takumi [1 ]
Matsuzaki, Juntaro [1 ]
Yamamoto, Yusuke [1 ]
Sakurai, Takashi [2 ]
Aoki, Yoshiaki [4 ]
Takizawa, Satoko [5 ]
Niida, Shumpei [3 ]
Ochiya, Takahiro [1 ,6 ]
机构
[1] Natl Canc Ctr, Div Mol & Cellular Med, Tokyo, Japan
[2] Natl Ctr Geriatr & Gerontol, Ctr Comprehens Care & Res Memory Disorders, Obu, Aichi, Japan
[3] Natl Ctr Geriatr & Gerontol, Med Genome Ctr, Obu, Aichi, Japan
[4] Dynacom Co Ltd, Chiba, Japan
[5] Toray Industries Ltd, Kamakura, Kanagawa, Japan
[6] Tokyo Med Univ, Dept Mol & Cellular Med, Tokyo, Japan
关键词
biomarkers; cerebrovascular disorders; circulating microRNA; microarray analysis; serum; C-REACTIVE PROTEIN; EXTRACELLULAR VESICLES; BREAST-CANCER; BIOMARKERS; INFARCTION; MORTALITY;
D O I
10.1161/STROKEAHA.118.023648
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose Numerous studies have shown that circulating microRNAs (miRNAs) can be used as noninvasive biomarkers of various diseases. This study aimed to identify serum miRNAs that predict the risk of stroke. Methods The cases were individuals who had been diagnosed with cerebrovascular disorder by brain imaging. The controls were individuals with no history of stroke who had undergone a medical checkup. Serum miRNA profiling was performed for all participants using microarray analysis. Samples were divided into discovery, training, and validation sets. In the discovery set, which consisted of control samples only, serum miRNAs that correlated with the predicted risk of stroke, as calculated using 7 clinical risk factors, were identified by Pearson correlation analysis. In the training set, a discriminant model between cases and controls was constructed using the identified miRNAs, Fisher linear discrimination model with leave-one-out cross-validation and DeLong test. In the validation set, the predictive accuracy of the constructed model was calculated. Results First, in 1523 control samples (discovery set), we identified 10 miRNAs that correlated with a predicted risk of stroke. Second, in 45 controls and 87 cases (training set), we identified 7 of 10 miRNAs that significantly associated with cerebrovascular disorder (miR-1228-5p, miR-1268a, miR-1268b, miR-4433b-3p, miR-6090, miR-6752-5p, and miR-6803-5p). Third, a 3-miRNA combination model (miR-1268b, miR-4433b-3p, and miR-6803-5p) was constructed in the training set with a sensitivity of 84%, a specificity of 98%, and an area under the receiver operating characteristic curve of 0.95 (95% CI, 0.92-0.98). Finally, in 45 controls and 86 cases (validation set), the 3-miRNA model achieved a sensitivity of 80%, a specificity of 82%, and an area under the receiver operating characteristic of 0.89 (95% CI, 0.83-0.95) for cerebrovascular disorder. Conclusions We identified 7 serum miRNAs that could predict the risk of cerebrovascular disorder before the onset of stroke.
引用
收藏
页码:1510 / 1518
页数:9
相关论文
共 50 条
  • [1] MicroRNA-Based Metastasis Prediction
    Jandial, Rahul
    Choy, Cecilia
    NEUROSURGERY, 2015, 77 (02) : N18 - N18
  • [2] Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer
    Satomi-Tsushita, Natsuko
    Shimomura, Akihiko
    Matsuzaki, Juntaro
    Yamamoto, Yusuke
    Kawauchi, Junpei
    Takizawa, Satoko
    Aoki, Yoshiaki
    Sakamoto, Hiromi
    Kato, Ken
    Shimizu, Chikako
    Ochiya, Takahiro
    Tamura, Kenji
    PLOS ONE, 2019, 14 (09):
  • [3] Contribution of bioinformatics prediction in microRNA-based cancer therapeutics
    Banwait, Jasjit K.
    Bastola, Dhundy R.
    ADVANCED DRUG DELIVERY REVIEWS, 2015, 81 : 94 - 103
  • [4] A novel serum microRNA-based diagnostic panel for breast cancer
    Sadiq, A.
    Siddique, S.
    Khan, J. S.
    Matloob, N.
    Qamar, R.
    Butt, A. M.
    ANNALS OF ONCOLOGY, 2020, 31 : S258 - S258
  • [5] microRNA-based biomarker for dementia
    Toyama, Kensuke
    Mogi, Masaki
    Tsao, Philip S.
    AGING-US, 2019, 11 (05): : 1329 - 1330
  • [6] MicroRNA-Based Therapeutics for Cancer
    Wang, Vivien
    Wu, Wei
    BIODRUGS, 2009, 23 (01) : 15 - 23
  • [7] MicroRNA-based therapeutics in cancer
    Slack, F. J.
    HUMAN GENE THERAPY, 2016, 27 (11) : A23 - A23
  • [8] Improved Risk Stratification in Myeloma Using Microrna-Based Classifier
    Wu, Ping
    Agnelli, Luca
    Walker, Brian A.
    Todoerti, Katia
    Johnson, David C.
    Kaiser, Martin
    Wardell, Christopher P.
    Gregory, Walter M.
    Davies, Faith E.
    Brewer, Daniel
    Neri, Antonino
    Morgan, Gareth J.
    BLOOD, 2012, 120 (21)
  • [9] MicroRNA-Based Therapeutics for Cancer
    Vivien Wang
    Wei Wu
    BioDrugs, 2009, 23 : 15 - 23
  • [10] Improved risk stratification in myeloma using a microRNA-based classifier
    Wu, Ping
    Agnelli, Luca
    Walker, Brian A.
    Todoerti, Katia
    Lionetti, Marta
    Johnson, David C.
    Kaiser, Martin
    Mirabella, Fabio
    Wardell, Christopher
    Gregory, Walter M.
    Davies, Faith E.
    Brewer, Daniel
    Neri, Antonino
    Morgan, Gareth J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (03) : 348 - 359